Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines

Karim A. Sharif, Jeffrey A. Moscow, I. David Goldman

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Human RFC1 (hRFC1) transfected in transport-deficient methotrexate MTX(R)ZR-75-1 human breast carcinoma cells (MTX(R)ZR-75/RFC) were used to investigate the impact of hRFC1 overexpression on influx and concentrative transport of methotrexate (MTX). Eight-fold overexpression of hRFC1, as determined by northern analysis, resulted in a 4-fold increase in MTX influx accompanied by a 2.4-fold increase in the steady-state level of free drug as compared with wild-type ZR-75-1 cells when the extracellular MTX level was 0.5 μM. When extracellular MTX was increased to 10 μM, the increase in influx equaled the increase in the transmembrane chemical gradient for MTX in the transfectant relative to wild-type cells. By 50 min, ~ 16-20 and 25% of the intracellular 3H represented MTX polyglutamates by HPLC analysis at [MTX](c) = 0.5 and 10 μM in wild-type and transfected cells, respectively. Overexpression of hRFC1 enhanced sensitivity to MTX in MTX(R)ZR-75-1 cells by more than 250-fold. The data indicate that overexpression of hRFC1 in human cells results in comparable increases in influx and transmembrane gradients. This is different from what was reported when mouse RFC1 was transfected into murine leukemia cells, resulting in large, more symmetrical increases in the MTX bidirectional transport kinetics with a much smaller change in steady- state levels. The changes in the human cells transfected with hRFC1 however, were similar to what has been observed by other investigators when RFC1 expression is increased by low folate selective pressure.

Original languageEnglish (US)
Pages (from-to)1683-1689
Number of pages7
JournalBiochemical Pharmacology
Volume55
Issue number10
DOIs
StatePublished - May 15 1998

Fingerprint

Reduced Folate Carrier Protein
Methotrexate
Cells
Breast Neoplasms
Cell Line
Folic Acid

Keywords

  • Folate
  • Methotrexate
  • Reduced folate carrier
  • Transport

ASJC Scopus subject areas

  • Pharmacology

Cite this

Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines. / Sharif, Karim A.; Moscow, Jeffrey A.; Goldman, I. David.

In: Biochemical Pharmacology, Vol. 55, No. 10, 15.05.1998, p. 1683-1689.

Research output: Contribution to journalArticle

@article{427e0fd7e6d34d739807115e6ad04c3d,
title = "Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines",
abstract = "Human RFC1 (hRFC1) transfected in transport-deficient methotrexate MTX(R)ZR-75-1 human breast carcinoma cells (MTX(R)ZR-75/RFC) were used to investigate the impact of hRFC1 overexpression on influx and concentrative transport of methotrexate (MTX). Eight-fold overexpression of hRFC1, as determined by northern analysis, resulted in a 4-fold increase in MTX influx accompanied by a 2.4-fold increase in the steady-state level of free drug as compared with wild-type ZR-75-1 cells when the extracellular MTX level was 0.5 μM. When extracellular MTX was increased to 10 μM, the increase in influx equaled the increase in the transmembrane chemical gradient for MTX in the transfectant relative to wild-type cells. By 50 min, ~ 16-20 and 25{\%} of the intracellular 3H represented MTX polyglutamates by HPLC analysis at [MTX](c) = 0.5 and 10 μM in wild-type and transfected cells, respectively. Overexpression of hRFC1 enhanced sensitivity to MTX in MTX(R)ZR-75-1 cells by more than 250-fold. The data indicate that overexpression of hRFC1 in human cells results in comparable increases in influx and transmembrane gradients. This is different from what was reported when mouse RFC1 was transfected into murine leukemia cells, resulting in large, more symmetrical increases in the MTX bidirectional transport kinetics with a much smaller change in steady- state levels. The changes in the human cells transfected with hRFC1 however, were similar to what has been observed by other investigators when RFC1 expression is increased by low folate selective pressure.",
keywords = "Folate, Methotrexate, Reduced folate carrier, Transport",
author = "Sharif, {Karim A.} and Moscow, {Jeffrey A.} and Goldman, {I. David}",
year = "1998",
month = "5",
day = "15",
doi = "10.1016/S0006-2952(98)00039-2",
language = "English (US)",
volume = "55",
pages = "1683--1689",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Concentrating capacity of the human reduced folate carrier (hRFC1) in human ZR-75 breast cancer cell lines

AU - Sharif, Karim A.

AU - Moscow, Jeffrey A.

AU - Goldman, I. David

PY - 1998/5/15

Y1 - 1998/5/15

N2 - Human RFC1 (hRFC1) transfected in transport-deficient methotrexate MTX(R)ZR-75-1 human breast carcinoma cells (MTX(R)ZR-75/RFC) were used to investigate the impact of hRFC1 overexpression on influx and concentrative transport of methotrexate (MTX). Eight-fold overexpression of hRFC1, as determined by northern analysis, resulted in a 4-fold increase in MTX influx accompanied by a 2.4-fold increase in the steady-state level of free drug as compared with wild-type ZR-75-1 cells when the extracellular MTX level was 0.5 μM. When extracellular MTX was increased to 10 μM, the increase in influx equaled the increase in the transmembrane chemical gradient for MTX in the transfectant relative to wild-type cells. By 50 min, ~ 16-20 and 25% of the intracellular 3H represented MTX polyglutamates by HPLC analysis at [MTX](c) = 0.5 and 10 μM in wild-type and transfected cells, respectively. Overexpression of hRFC1 enhanced sensitivity to MTX in MTX(R)ZR-75-1 cells by more than 250-fold. The data indicate that overexpression of hRFC1 in human cells results in comparable increases in influx and transmembrane gradients. This is different from what was reported when mouse RFC1 was transfected into murine leukemia cells, resulting in large, more symmetrical increases in the MTX bidirectional transport kinetics with a much smaller change in steady- state levels. The changes in the human cells transfected with hRFC1 however, were similar to what has been observed by other investigators when RFC1 expression is increased by low folate selective pressure.

AB - Human RFC1 (hRFC1) transfected in transport-deficient methotrexate MTX(R)ZR-75-1 human breast carcinoma cells (MTX(R)ZR-75/RFC) were used to investigate the impact of hRFC1 overexpression on influx and concentrative transport of methotrexate (MTX). Eight-fold overexpression of hRFC1, as determined by northern analysis, resulted in a 4-fold increase in MTX influx accompanied by a 2.4-fold increase in the steady-state level of free drug as compared with wild-type ZR-75-1 cells when the extracellular MTX level was 0.5 μM. When extracellular MTX was increased to 10 μM, the increase in influx equaled the increase in the transmembrane chemical gradient for MTX in the transfectant relative to wild-type cells. By 50 min, ~ 16-20 and 25% of the intracellular 3H represented MTX polyglutamates by HPLC analysis at [MTX](c) = 0.5 and 10 μM in wild-type and transfected cells, respectively. Overexpression of hRFC1 enhanced sensitivity to MTX in MTX(R)ZR-75-1 cells by more than 250-fold. The data indicate that overexpression of hRFC1 in human cells results in comparable increases in influx and transmembrane gradients. This is different from what was reported when mouse RFC1 was transfected into murine leukemia cells, resulting in large, more symmetrical increases in the MTX bidirectional transport kinetics with a much smaller change in steady- state levels. The changes in the human cells transfected with hRFC1 however, were similar to what has been observed by other investigators when RFC1 expression is increased by low folate selective pressure.

KW - Folate

KW - Methotrexate

KW - Reduced folate carrier

KW - Transport

UR - http://www.scopus.com/inward/record.url?scp=0032525038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032525038&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(98)00039-2

DO - 10.1016/S0006-2952(98)00039-2

M3 - Article

VL - 55

SP - 1683

EP - 1689

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -